Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643502 | 0.87 | KDM4E (0.43) | KDM4EHSD17B10NPC1RAB9ACA12 | |
| SCHEMBL2654537 | 0.86 | KDM4E (0.43) | KDM4EHSD17B10NPC1RAB9ACA12 | |
| SCHEMBL9903306 | 0.83 | KDM4E (0.49) | KDM4EHSD17B10RAB9ACA12CA1 | |
| SCHEMBL644235 | 0.80 | CA12 (0.51) | HSD17B10NPC1CA12CA1CA2 | |
| SCHEMBL2813926 | 0.80 | KDM4E (0.44) | KDM4EHSD17B10NPC1RAB9ACA12 | |
| SCHEMBL645828 | 0.80 | CA12 (0.44) | KDM4EHSD17B10NPC1RAB9ACA12 | |
| SCHEMBL643349 | 0.78 | CA12 (0.38) | KDM4EHSD17B10RAB9ACA12CA1 | |
| SCHEMBL692586 | 0.76 | CA12 (0.53) | KDM4EHSD17B10NPC1RAB9ACA12 | |
| SCHEMBL642512 | 0.75 | GCK (0.60) | HPGDGCK | |
| SCHEMBL12101429 | 0.75 | PTGS2 (0.43) | HPGDGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-8735396-B2 | Benzofuranyl derivatives | PFIZER INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735396-B2 | Benzofuranyl derivatives | PFIZER INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735396-B2 | Benzofuranyl derivatives | PFIZER INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130252973-A1 | Benzofuranyl Derivatives | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252973-A1 | Benzofuranyl Derivatives | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252973-A1 | Benzofuranyl Derivatives | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| EP-2406253-B1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2406253-B1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2604604-A1 | Benzofuranyl derivatives used as glucokinase inhibitors | Pfizer Inc (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20100234285-A1 | Benzofuranyl Derivatives | PFIZER INC | 2010-09-16 | — | — | US | disclosed |
| US-20100234285-A1 | Benzofuranyl Derivatives | PFIZER INC | 2010-09-16 | — | — | US | disclosed |
| US-20100234285-A1 | Benzofuranyl Derivatives | PFIZER INC | 2010-09-16 | — | — | US | disclosed |
| WO-2010103437-A1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234285-A1 | Benzofuranyl Derivatives | GCK, GCKR, GALK1 | KDM4E 2117/4885HSD17B10 587/4885NPC1 1373/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | KDM4E 1790/4885HSD17B10 1912/4885NPC1 1969/4885 |
| US-20130252973-A1 | Benzofuranyl Derivatives | GCK, GCKR, GALK1 | KDM4E 2117/4885HSD17B10 587/4885NPC1 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.